Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related MRK
Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine
Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS
Biotech Forum Daily Digest: Will Biotech Finally Break Out? All Eyes On Gilead, Spotlight On Seres Therapeutics (Seeking Alpha)
Related JOY
Benzinga's Top Upgrades
Benzinga's M&A Chatter for Thursday July 21, 2016:
Higher Buyout Price For Joy Global Is Expected By Investors (Seeking Alpha)

Analysts at MKM Partners upgraded Merck & Co (NYSE: MRK) from “neutral” to “buy.” Merck's shares closed at $43.34 yesterday. Merck's trailing-twelve-month revenue is $47.82 billion.

Analysts at BMO Capital upgraded Joy Global (NYSE: JOY) from “underperform” to “market perform.” Joy Global's stock closed at $57.07 yesterday. Joy Global's trailing-twelve-month operating margin is 21.17%.

Analysts at Jefferies upgraded Research In Motion Limited (NASDAQ: RIMM) from “underperform” to “hold.” Research In Motion's shares closed at $9.59 yesterday. Research In Motion had $2.06 billion in total cash for the latest quarter.

Analysts at Goldman Sachs upgraded Whole Foods Market (NASDAQ: WFM) from “neutral” to “buy.” Whole Foods Market's shares closed at $91.41 yesterday. Whole Foods Market's trailing-twelve-month ROE is 13.71%.

Latest Ratings for MRK

DateFirmActionFromTo
Jul 2016BMO CapitalDowngradesOutperformMarket Perform
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (MRK + JOY)

View Comments and Join the Discussion!